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Abstract
Background: Combined chemo- and radiotherapy are established in breast cancer treatment. Chemotherapy is recommended
prior to radiotherapy but decisive data on the optimal sequence are rare. This retrospective analysis aimed to assess the role
of sequencing in patients after mastectomy because of advanced locoregional disease.
Methods: A total of 212 eligible patients had a stage III breast cancer and had adjuvant chemotherapy and radiotherapy after
mastectomy and axillary dissection between 1996 and 2004. According to concerted multi-modality treatment strategies 86
patients were treated sequentially (chemotherapy followed by radiotherapy) (SEQgroup), 70 patients had a sandwich treatment
(SW-group) and 56 patients had simultaneous chemoradiation (SIM-group) during that time period. Radiotherapy comprised the
thoracic wall and/or regional lymph nodes. The total dose was 45–50.4 Gray. As simultaneous chemoradiation CMF was given
in 95.4% of patients while in sequential or sandwich application in 86% and 87.1% of patients an anthracycline-based
chemotherapy was given.
Results: Concerning the parameters nodal involvement, lymphovascular invasion, extracapsular spread and extension of the
irradiated region the three treatment groups were significantly imbalanced. The other parameters, e.g. age, pathological tumor
stage, grading and receptor status were homogeneously distributed. Looking on those two groups with an equally effective
chemotherapy (EC, FEC), the SEQ- and SW-group, the sole imbalance was the extension of LVI (57.1 vs. 25.6%, p < 0.0001).
5-year overall- and disease free survival were 53.2%/56%, 38.1%/32% and 64.2%/50%, for the sequential, sandwich and
simultaneous regime, respectively, which differed significantly in the univariate analysis (p = 0.04 and p = 0.03, log-rank test).
Also the 5-year locoregional or distant recurrence free survival showed no significant differences according to the sequence of
chemo- and radiotherapy. In the multivariate analyses the sequence had no independent impact on overall survival (p = 0.2) or
disease free survival (p = 0.4). The toxicity, whether acute nor late, showed no significant differences in the three groups. The
grade III/IV acute side effects were 3.6%, 0% and 3.5% for the SIM-, SW- and SEQ-group. By tendency the SIM regime had more
late side effects.
Conclusion: No clear advantage can be stated for any radio- and chemotherapy sequence in breast cancer therapy so far. This
could be confirmed in our retrospective analysis in high-risk patients after mastectomy. The sequential approach is
recommended according to current guidelines considering a lower toxicity.
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Adjuvant chemotherapy and radiotherapy were estab-
lished in the multidisciplinary treatment of breast cancer.
Generally, radiotherapy is used after completion of adju-
vant chemotherapy but decisive data for a scientifically
based decision on the optimal sequence are not known.
The majority of published data are related to early breast
cancer (stage I-II). The only existing randomized study
questioning the optimal sequencing of radio- and chemo-
therapy in early breast cancer found no substantial differ-
ences in locoregional or distant recurrence between the
treatment arms [1,2]. But in patients with locoregional
advanced breast cancer (stage III) surgically treated with
mastectomy and axillary dissection, no data on the opti-
mal chemo- and radiotherapy sequence exists. The objec-
tive of our retrospective study was to evaluate the clinical
outcome of our female patients with locoregional
advanced breast cancer after mastectomy and adjuvant
radiotherapy, with a specific interest on the role of
sequencing chemo- and radiotherapy.
Methods
In the database of the Department of Radiation Oncology,
343 female patients were found to have mastectomy with
axillary dissection and adjuvant radiotherapy, following
the diagnosis of unilateral locoregional advanced invasive
breast cancer in the time period from January 1996 to
June 2004. Eligible criteria for the retrospective analysis
were a stage III breast cancer treated with mastectomy and
adjuvant chemo- and radiotherapy. A cohort of 212
patients fulfilled the criteria and was included in our anal-
ysis.
The data presented in this analysis were acquired retro-
spectively and anonymously. According to the regulations
of the German Medical Association no official approval
by the local ethics committee was necessary. All patients
had a primary locoregional advanced disease, character-
ized by a pT3/pT4 tumor in 41.9% of patients, an involve-
ment of at least four axillary lymph nodes (60.8% of
patients) and evidence of multicentricity in 36.3% of
patients. An inflammatory disease was seen in 3.4% of the
included patients. The surgical procedure was performed
in the Department of Gynaecology and Obstetrics at the
University Hospital Aachen and at corresponding experi-
enced Departments of Gynaecology from four regional
hospitals. In periodical conferences, all patients were dis-
cussed and the therapeutic approach determined. After
surgery all patients were irradiated in the Dept. of Radia-
tion Oncology, RWTH Aachen University Hospital.
Surgery included modified radical mastectomy or, in a few
patients simple mastectomy and in all patients axillary
lymph node dissection (usually levels I and II). An imme-
diate reexcision was performed in 12 patients (5.7%) with
microscopically incomplete resection. Finally the patho-
logical margin was negative in 92.9% of the patients.
Following surgery, all women received adjuvant chemo-
therapy and adjuvant external beam radiotherapy.
The patient age ranged from 34 to 92 (median 64) years.
The patients were grouped according to the sequence of
chemotherapy and radiotherapy. A group of 86 patients
(40.6%) was treated sequentially (SEQ-group) which
means that radiotherapy was applied after finishing the
last chemotherapy cycle. Seventy patients (33.9%) were
treated in a sandwich scheme (SW-group) which means
that 2–4 chemotherapy cycles were given prior to radio-
therapy followed by 2–4 further chemotherapy cycles, and
56 patients (26.4%) were treated with simultaneous
chemo- and radiotherapy (SIM-group) in the years
1996–1999. In the SEQ- and the SW-group most of the
patients (86% and 87.1%) had an antracycline-based
chemotherapy regime (EC or FEC) while in the SIM-group
a CMF chemotherapy was given in 95.4% of patients.
From the patho-histological examination 158 (74.5%)
and 35 (16.5%) patients had ductal-invasive and lobular-
invasive breast cancer, respectively. Nineteen (9%)
patients had a rare histology (medullary (n = 8), papillary
(n = 4), tubular (n = 2), other (n = 5)).
A total of 158 patients (74.5%) had positive estrogen and/
or progesterone receptors and usually received an adju-
vant antihormonal therapy.
Radiotherapy was performed typically. The ipsilateral
supra- and infraclavicular lymph nodes and the axilla
(SIA) were irradiated with anterior-posterior (ap)- or ante-
rior-posterior/posterior-anterior (ap/pa)- fields with 6–10
megaelectron volt (MeV) photons. The thoracic wall
(THW) and the ipsilateral parasternal lymph nodes were
irradiated with individually shaped electron fields with
4–12 and 10–15 MeV. The total dose in all fields was
45–50.4 Gray (Gy) in daily fractions of 1.8–2 Gy.
All patients gave written informed consent to surgery,
radiotherapy and chemotherapy, separately.
The radiotherapy induced acute and late toxicity was ana-
lyzed according to the RTOG- (Radiation Therapy Oncol-
ogy Group) scoring system related to the radiotherapy
specific side effects as skin erythema, teleangiectasia,
hyperpigmentation, fibrosis and arm edema.
The mean follow-up was 34.7 (standard deviation (SD):
20.2, min: 2.8, max: 103) months.Page 2 of 9
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total sample as well as separately for the subgroups of
sequential, sandwich or simultaneous chemo- and radio-
therapy, is summarized in table 1.
Statistical methods
Continuous variables were summarized by minimum,
maximum, mean and corresponding standard deviation.
Categorical data were condensed by absolute and relative
values.
Cross tabulations were created to compare frequency dis-
tributions between subgroups (sequential, sandwich,
simultaneous). The Pearson x2-test was used to assess
whether the associations displayed in those cross tabula-
tions are statistically significant.
The observation period started at the time of surgery.
Overall survival (OS)- and disease free survival (DFS)-
curves were estimated according to the Kaplan-Meier
method. The log-rank test was used for global comparison
of OS- and DFS-curves between the subgroups according
to the following variables: sequencing of chemo- and radi-
otherapy (SEQchemoRT), age, histological type, pathologi-
cal tumor stage (pT), pathological nodal stage (pN),
lymphovascular involvement (LVI), grading (G), receptor
status (Rec), extracapsular spread (ECS), resection status
(R), vascular involvement (V) and irradiated regions
(RTregion). Moreover, multivariate Cox regression analy-
ses were carried out in order to investigate which of these
variables are independent prognostic factors with respect
to OS and DFS.
To allow for a better interpretability of the results reached
in those Cox regression analyses, for each of the two
response variables (OS, DFS) only factors showing a p-
value of ≤ 0.1 in the corresponding univariate log-rank
analysis were incorporated as independent variables in
the according Cox regression models. Additionally local
recurrence free survival (LRS)- and distant recurrence free
survival (DRS)- curves were estimated according to the
Kaplan-Meier method and the log-rank test was used for
Table 1: Distribution of categorical parameters in patients with sequential, sandwich or simultaneous chemo- and radiotherapy (a done 
by Pearson x2-test)
Sequencing of chemo- and radiotherapy
all patients n = 212 sequential n = 86 sandwich n = 70 simultaneous n = 56 pa (two-sided)
Age n (%) age ≤ 50 41 (19.3) 14 (16.3) 15 (21.4) 12 (21.4) 0.7
age > 50 171 (80.7) 72 (83.7) 55 (78.6) 44 (78.6)
histological type n (%) ductal-invasiv 158 (74.5) 65 (79.3) 48 (68.6) 45 (80.4) 0.7
ductal-lobular 35 (16.5) 14 (17.1) 14 20) 7 (12.5)
other 19 (9) 7 (8.1) 8 (11.4) 4 (7.1)
pT n (%) pT1/2 123 (58) 53 (61.6) 40 (57.1) 30 (53.6) 0.4
pT3/4 89 (42) 33 (38.4) 30 (42.9) 26 (46.4)
pN n (%) pN0 48 (22.6) 12 (14) 14 (20) 22 (39.3) 0.004
pN1 35 (16.5) 18 (20.9) 8 (11.4) 9 (16.1)
pN2-3 129 (60.9) 56 (65.1) 48 (68.6) 25 (44.6)
LVI n (%) yes 77 (36.3) 22 (25.6) 40 (57.1) 15 (26.8) < 0.0001
no 135 (63.7) 64 (74.4) 30 (42.9) 41 (73.2)
G n (%) G1 5 (2.4) 3 (3.5) 1 (1.4) 1 (1.8) 0.2
G2 89 (42) 36 (41.9) 23 (32.9) 30 (53.6)
G3 118 (55.7) 47 (54.7) 46 (65.7) 25 (44.6)
ECS n (%) yes 110 (51.9) 50 (58.1) 41 (58.6) 19 (33.9) 0.007
no 102 (48.1) 36 (41.9) 29 (41.4) 37 (66.1)
Receptor (ER and/or 
PR) n (%)
positive 158 (74.5) 66 (76.7) 53 (75.7) 39 (69.6) 0.6
negative 54 (25.5) 20 (23.3) 17 (24.3) 17 (30.4)
R n (%) R0 197 (92.9) 81 (94.2) 64 (91.4) 52 (92.9) 0.9
R+ 15 (7.1) 5 (5.8) 6 (8.6) 4 (7.1)
V n (%) yes 194 (91.5) 81 (94.2) 60 (85.7) 53 (94.6) 0.1
no 18 (8.5) 5 (5.8) 10 (14.3) 3 (5.4)
RT region n (%) 
parasternal fields (in 
28.3% created) not 
separately considered
THW + SIA 148 (69.8) 62 (72.1) 56 (80) 30 (53.6) 0.01
THW only 17 (8) 6 (7) 6 (8.6) 5 (8.9)
SIA only 47 (22.2) 18 (20.9) 8 (11.4) 21 (37.5)Page 3 of 9
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sequencing of chemo- and radiotherapy.
The global significance level for all statistical test proce-
dures conducted was chosen as α = 5%. All statistical anal-
yses were conducted in an explorative manner. Thus, with
consideration of the explorative character of the analysis,
p-values of p ≤ 0.05 can be interpreted as statistically sig-
nificant test results. All statistical analyses were carried out
using the statistical analysis software package SPSS, ver-
sion 14.0 (SPSS Inc., Chicago, IL, USA).
Results
The distribution of the patients categorical parameters
stratified by the chemotherapy sequence is presented in
table 1. Concerning the parameters nodal involvement
(pN), lymphovascular invasion (LVI), extracapsular
spread (ECS) and extension of the irradiated region (RTre-
gion) the three treatment groups were significantly imbal-
anced. The other parameters, e.g. age, pathological tumor
stage (pT), grading (G) and receptor status were homoge-
neously distributed. Looking on those two groups with an
equally effective chemotherapy (EC, FEC), the SEQ- and
SW-group, the sole imbalance was the extension of LVI
(57.1 vs. 25.6%, p < 0.0001).
The 5-year overall and disease free survival rate was 53%
and 46% for all 212 patients, respectively (table 2).
Depending on the sequence of chemotherapy and radio-
therapy the 5-year overall or disease free survival rates
were 53.2% or 56% (SEQ-group), 38.1% or 32% (SW-
group) and 64.2% or 50% (SIM-group), respectively
(table 2). There was a significantly difference in 5-year OS
and DFS depending on the sequencing of chemo- and
Table 2: 5-year overall- and disease free survival rates depending on subgroups of prognostic factors (* p-values of log-rank tests 
comparing survival times between subgroups)
5-year OS rate 5-year DFS rate
% p* % p*
All patients n (%) 212 (100 %) 53 46
Sequencing of chemo- and radiotherapy n (%) SEQ 86 (40.6) 53.2 0.04 56 0.03
SW 70 (33) 38.1 32
SIM 56 (26.4) 64.2 50
Age n (%) age ≤ 50 41 (19.3) 59.4 0.9 52.2 0.6
age > 50 171 (80.7) 52.2 45.3
histological type n (%) ductal-invasiv 158 (74.5) 54.2 0.6 47.8 0.6
ductal-lobular 35 (16.5) 47.6 45.2
other 19 (9) 46.8 0
pT n (%) pT1 33 (15.6) 70.6 0.06 70.8 0.03
pT2 90 (42.5) 59.8 44.4
pT3 41 (19.3) 54.2 45.1
pT4 48 (22.6) 31.4 36.8
pN n (%) pN0 48 (22.6) 65.7 0.1 52.2 0.1
pN1 35 (16.5) 53.8 53.4
pN2-3 129 (60.8) 48.5 42.1
LVI n (%) yes 77 (36.3) 40.4 0.01 34.9 0.001
no 135 (63.7) 59.4 52.9
G n (%) G1 5 (2.4) 33.1 0.04 53.3 0.3
G2 89 (42) 63.2 49.5
G3 118 (55.7) 46.2 44.6
ECS n (%) yes 110 (51.9) 44.8 0.04 40.2 0.01
no 102 (48.1) 61.8 52.2
Receptor (ER and/or PR) n (%) positive 158 (74.5) 56.7 0.07 48.1 0.2
negative 54 (25.5) 41.3 40.0
R n (%) R0 197 (92.9) 53.3 0.8 47.3 0.04
R+ 15 (7.1) 56.7 35.0
V n (%) yes 194 (91.5) 0 0.03 0 0.002
no 18 (8.5) 55.0 48.3
RT region n (%) parasternal fields (in 28.3% created) not 
separately considered
THW +SIA 148 (69.8) 52.2 0.4 51.9 0.4
THW alone 17 (8) 72.8 0
SIA alone 47 (22.2) 50.6 36.6Page 4 of 9
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0.03, log-rank test (table 2 and 3, figure 1).
Patients in the SEQ-group (n = 86), SW-group (n = 70)
and SIM-group (n = 56) had a locoregional and/or distant
recurrence in 44%, 68% and 50% within five years,
respectively. Patients in the SW-group, which had the
highest percentage of LVI (57.1% vs. 25.6% (SEQ-group)
vs. 26.8% (SIM-group)), revealed a low 5-year locore-
gional recurrence free survival rate (LRS, 57.9%) together
with a low distant metastases free survival rate (DMS,
49.8%). In dependence on the sequencing of chemo- and
radiotherapy no significantly differences could be shown
in 5-year locoregional or distant recurrence free survival
rates (p = 0.09 and p = 0.1, log-rank test) (table 3 and fig-
ures 2, 3, 4).
Moreover the variables LVI, ECS, grading and vascular
involvement had significant impact on overall survival
times in the univariate analyses (table 2).
In the multivariate analyses (Cox regression) the sequenc-
ing of chemo- and radiotherapy showed no independent
significant impact on OS (p = 0.2) or DFS (p = 0.4). Only
the receptor status revealed an independent influence on
OS (p = 0.04), but not on DFS (p = 0.2) (table 4).
Discussion
The optimal sequencing of adjuvant chemotherapy and
radiotherapy in breast cancer patients remains controver-
sial [3]. On the one hand retrospective studies suggest an
increase of local recurrence rates when radiotherapy was
delayed in favour of finishing chemotherapy [4-6]. On the
other hand an increase in distant recurrence was reported
when radiotherapy was given first [7-9]. First results from
the only existing prospective, randomized trial to proof
the question whether the chemotherapy-radiotherapy or
radiotherapy-chemotherapy sequence is better was pub-
lished 1996 by Recht et al. [2]. Patients in the radiother-
apy first arm had a lower rate of local recurrence (5% vs.
14%) and a higher 5-year crude rate of distant/regional
recurrence (32% vs. 20%) compared to patients in the
chemotherapy first arm. The 5-year survival rate of distant
recurrence was statistically significant higher in the radio-
therapy first arm compared to the rate in the chemother-
apy first arm (36% vs. 25%). The updated results with a
follow-up of 135 months were published by Bellon et al.
in 2005 and showed the loss of significant differences in
local or distant recurrence rates between the two treat-
ment arms [1]. Certainly the authors pointed out, that the
trial was underpowered to detect small differences in sur-
vival times for either sequence. Several other groups
found no crucial differences in survival or recurrence rates
depending on the sequencing of chemotherapy and radi-
otherapy, too [7,8,10]. A limiting fact in the assessment of
the role of chemotherapy-radiotherapy sequencing may
be the use of older chemotherapy regimes, i.e. CMF,
which are not appropriate in modern strategies for sys-
temic treatment [11].
Most literature data refer to early breast cancer treated
with breast conserving surgery. Data suggesting how to
sequence chemotherapy and radiotherapy in a high-risk
patient group after mastectomy because of locally or loco-
regionally advanced breast cancer are very rare. The objec-
tive of our analysis was to assess the impact of different
sequencing strategies by looking on a patient cohort,
which is nevertheless characterized by the process of
improvements in chemotherapy strategies.
A total of 212 patients were included in our retrospective
analysis. All patients were treated with mastectomy and
axillary dissection followed by adjuvant chemotherapy
and radiotherapy in the years 1996–2004. In the years
1996 to 1999 CMF, given in 6 cycles, was recommended
[12,13] and the mostly used chemotherapy regime in our
cohort. Later anthracycline-containing regimes were
implemented according to current data [14,15]. The
Table 3: 5-year overall, disease free, locoregional recurrence free- and distant recurrence free survival rates depending on the 
sequencing of chemo- and radiotherapy
5-year OS rate 5-year DFS rate 5-year LRS rate 5-year DRS rate
% p* % p* % p* % p*
All patients n (%) 212 (100 %) 53 46 75.7 56.4
Sequencing of 
chemo- and 
radiotherapy n 
(%)
SEQ 86 (40.6) 53.2 0.04 56 0.03 88 0.09 60.2 0.1
SW 70 (33) 38.1 32 57.9 49.8
SIM 56 (26.4) 64.2 50 77.4 59.8
(* p-values of log-rank tests comparing survival times between different sequences)Page 5 of 9
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or as a sandwich scheme. The decision was based on the
estimation of the risk of local or systemic risk. In patients
of a predominately local risk, i.e. close surgical margin or
peritumoral lymphovascular invasion, a sandwich
scheme was preferred. In the other patients with predom-
inately systemic risk, i.e. extensive nodal involvement, the
sequential regime was preferred. As from 2003 the
sequential regime, given as six cycles FEC prior to radio-
therapy was used principally following the current ten-
dency [16] and national recommendations [17].
The 5-year overall (OS) and disease free survival rates
(DFS) were 53% and 46%, respectively. The correspond-
ing 5-year locoregional (LRS) and distant recurrence free
Kaplan-Maier curve of distant recurrence free survivalFigure 4
Kaplan-Maier curve of distant recurrence free sur-
vival.
Kaplan-Maier curves of disease free survivalFigure 2
Kaplan-Maier curves of disease free survival.
Kaplan-Maier curves of overall survivalFigure 1
Kaplan-Maier curves of overall survival.
Kaplan-Maier curve of local recurrence free survivalFigure 3
Kaplan-Maier curve of local recurrence free survival.Page 6 of 9
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taking all patients into account.
Crucial prognostic factors for OS and DFS are the number
of involved axillary lymph nodes [18-21] and lymphatic
vessel invasion (LVI) [22,23]. Extracapsular spread in axil-
lary lymph node metastases had likewise a crucial impact
on the prognosis [22,24-26].
Our patients belong to a high-risk collective. A total of
60.9 % of our patients had ≥ 4 axillary lymph node metas-
tases, 36.3% had a LVI and 51.9% had an ECS. On average
7 (SD: 7.7) axillary lymph nodes were involved. Regard-
ing the distribution of these prognostic factors OS and
DFS in our analysis was comparable to the literature data.
Overgaard et al. reported better 5-year OS and DFS rates
(72% and 61%) but only 29.1% of the patients had ≥ 4
axillary metastases [27]. Ragaz et al. reported 5-year-OS
and DFS rates of 60% and 47% for patients with ≥ 4 axil-
lary lymph node metastases, comparable to our data [28].
In the univariate analysis patients treated with the sand-
wich regime had a clearly worse 5-year OS and DFS
(38.1% and 32%) compared to the sequential (53.2% and
56%) and simultaneous (64.2% and 50%) regime (p =
0.04 for OS and p = 0.03 for DFS, log-rank test). In the
multivariate analysis (table 4), conducted to assess the
independent influence of various prognostic factors the
sequence of chemo- and radiotherapy showed no statisti-
cally significant impact on OS (p = 0.2) or DFS (p = 0.4)
anymore. The 5-year locoregional- and distant recurrence
free survival rates were not statistically significant different
in the three groups (p = 0.09 and p = 0.1, log-rank test),
too. For OS only the receptor status and for DFS no
parameter revealed independent prognostic influence in
multivariate Cox regression analysis.
It must be pointed out that the distribution of patient-
and tumor-related parameters in our patient groups was
unbalanced. In the SW- and SEQ-group significantly more
patients had ≥ 4 axillary lymph node metastases (68.6%
and 65.1%) compared to the SIM-group (44.6%). A LVI
appeared most frequent in the SW-group (57.1%), an ECS
in the SW- and SEQ-group (58.6% and 58.1%) (table 1).
The acute and late toxicity data are comparable to the data
reported by Markiewicz et al. [29]. The authors analysed
the data from 1053 patients concerning the effects of
sequence and type of chemotherapy and radiotherapy on
cosmesis and complications after breast conserving sur-
gery and found no statistically significant differences.
Because of the imbalances in parameter distributions the
results of a retrospective analysis should be interpreted
carefully, especially considering the prognostic value of
tumor-related factors, like LVI.
In our opinion the use of sequential regimes is state of the
art. Simultaneous CMF is feasible concerning the toxicity,
but no longer in general use for adjuvant breast cancer
therapy [30].
By now the use of anthracyclines is standard in breast can-
cer chemotherapy and the use of taxanes is clearly increas-
ing, especially in patients with locoregional advanced
disease. The simultaneous use of anthracyclines is more
than critical because of the known radiosensitizing effect
and at least not recommended [11,31-34]. Also paclitaxel
simultaneous to radiotherapy leads to higher toxicity,
such as pneumonitis and skin reactions [11,35,36].
Conclusion
So far in the literature no prognostic advantage can be
stated for any radio- and chemotherapy sequence in early
breast cancer therapy [1,37]. These findings could be con-
firmed in our analysis in high-risk patients after perform-
ing mastectomy. The weakness of retrospective analyses in
balancing prognostic factors relativized basically the
assessment of the role of sequencing radio- and chemo-
therapy. In favour to lower toxicity the sequential
approach is always recommended. Furthermore radio-
therapy should follow chemotherapy according to current
guidelines [11,38,39].
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